Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Willis Tower Watson in its divestment of Max Matthiessen
Mandate

Vinge advises Willis Tower Watson in its divestment of Max Matthiessen

May 25, 2020 Banking and Finance EU, Competition and Regulatory M&A Insurance Law Corporate Tax

Vinge advises Willis Tower Watson, global risk adviser, insurance and reinsurance broker, in its divestment of Max Matthiessen to Nordic Capital.

Max Matthiessen was founded 1889 and as active in insurance brokerage and financial advisory services for companies and individuals. The company has 440 employees at approximately 30 locations throughout Sweden with headquarter in Stockholm. In 2019, Max Matthiessen had a customer base of around 13,000 clients with revenues exceeding SEK 1.5 billion. Willis Tower Watson acquired Max Matthiessen from Altor 2014.

The acquisition is conditional upon customary regulatory approvals and conditions to closing.

Vinge’s team consisted of, amongst others, Peter Sundgren, Joacim Rydergård, Stina Bengtsson and Olivia Belding (M&A), Fabian Ekeblad and Paulina Malmberg (Regulatory Insurance), Albert Wållgren (Banking & Finance), Maria Schultzberg (Tax), Xandra Ståhlberg (Competition law) and Nathalie Hughes (VDR-assistant).

 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025